MXPA05010555A - Formulaciones de proteina y anticuerpo de alta concentracion. - Google Patents

Formulaciones de proteina y anticuerpo de alta concentracion.

Info

Publication number
MXPA05010555A
MXPA05010555A MXPA05010555A MXPA05010555A MXPA05010555A MX PA05010555 A MXPA05010555 A MX PA05010555A MX PA05010555 A MXPA05010555 A MX PA05010555A MX PA05010555 A MXPA05010555 A MX PA05010555A MX PA05010555 A MXPA05010555 A MX PA05010555A
Authority
MX
Mexico
Prior art keywords
formulations
high concentration
protein
protein formulations
antibody
Prior art date
Application number
MXPA05010555A
Other languages
English (en)
Inventor
Steven J Shire
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33299719&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05010555(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MXPA05010555A publication Critical patent/MXPA05010555A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/80—Elimination or reduction of contamination by undersired ferments, e.g. aseptic cultivation

Abstract

La presente solicitud se refiere a formulaciones de anticuerpo y proteina altamente concentradas con viscosidad reducida, que son estables, relativamente isotonicas y de baja turbiedad. Las formulaciones son particularmente convenientes para administracion subcutanea. La solicitud ademas describe articulos de manufactura que contienen dichas formulaciones y a metodo para utilizar las para tratar desordenes que se tratan por el anticuerpo o proteina formulada.
MXPA05010555A 2003-04-04 2004-03-29 Formulaciones de proteina y anticuerpo de alta concentracion. MXPA05010555A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46065903P 2003-04-04 2003-04-04
PCT/US2004/009613 WO2004091658A1 (en) 2003-04-04 2004-03-29 High concentration antibody and protein formulations

Publications (1)

Publication Number Publication Date
MXPA05010555A true MXPA05010555A (es) 2006-03-09

Family

ID=33299719

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05010555A MXPA05010555A (es) 2003-04-04 2004-03-29 Formulaciones de proteina y anticuerpo de alta concentracion.

Country Status (36)

Country Link
US (7) US20040197324A1 (es)
EP (3) EP2335725B1 (es)
JP (2) JP4869064B2 (es)
KR (2) KR101208291B1 (es)
CN (2) CN102258464A (es)
AR (2) AR043826A1 (es)
AT (1) ATE480567T1 (es)
AU (2) AU2004229335C1 (es)
BR (1) BRPI0403964B8 (es)
CA (1) CA2519408C (es)
CL (3) CL2004000731A1 (es)
CO (1) CO5660273A2 (es)
CY (2) CY1111232T1 (es)
DE (1) DE602004029015D1 (es)
DK (2) DK2335725T3 (es)
EC (2) ECSP056142A (es)
ES (2) ES2349779T5 (es)
HK (1) HK1085933A1 (es)
HR (1) HRP20050934B1 (es)
HU (1) HUE030579T2 (es)
IL (2) IL170866A (es)
LT (1) LT2335725T (es)
MA (1) MA27773A1 (es)
MX (1) MXPA05010555A (es)
MY (1) MY172641A (es)
NO (3) NO338143B1 (es)
NZ (1) NZ542964A (es)
PE (1) PE20050394A1 (es)
PL (2) PL2335725T3 (es)
PT (2) PT1610820E (es)
RU (1) RU2332986C2 (es)
SI (1) SI2335725T1 (es)
TN (1) TNSN05229A1 (es)
TW (1) TWI357820B (es)
WO (1) WO2004091658A1 (es)
ZA (1) ZA200507757B (es)

Families Citing this family (260)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2382488T3 (es) 1997-03-21 2012-06-08 Chugai Seiyaku Kabushiki Kaisha Un agente preventivo o terapéutico para enfermedades mediadas por células t sensibilizadas que comprende un antagonista de il-6 como ingrediente activo
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DE60139944D1 (de) * 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
PT1610820E (pt) * 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US20070104714A1 (en) * 2003-08-29 2007-05-10 Cedars-Sinai Medical Center Composition and method for the treatment of cancer and other physiologic conditins based on modulation of the ppar-gamma pathway and her-kinase axis
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
MX350383B (es) 2004-01-09 2017-09-04 Pfizer Anticuerpos contra madcam.
WO2005072772A1 (en) * 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
US7319032B2 (en) 2004-04-22 2008-01-15 Medtox Non-sugar sweeteners for use in test devices
WO2005112893A1 (en) * 2004-05-12 2005-12-01 Baxter International Inc. Microspheres comprising protein and showing injectability at high concentrations of said agent
ES2442115T3 (es) * 2004-05-12 2014-02-10 Baxter International Inc. Microesferas que contienen oligonucleótidos, su utilización para la preparación de un medicamento para el tratamiento de la diabetes tipo 1
EP2072040B1 (en) 2004-05-12 2013-05-01 Baxter International Inc. Therapeutic use of nucleic acid micropheres
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
US7973134B2 (en) 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
AU2005272993B2 (en) 2004-07-15 2010-02-11 Xencor, Inc Optimized Fc variants
BRPI0513601A (pt) * 2004-07-23 2008-05-13 Genentech Inc métodos de produção de cristais de anticorpo ou seu fragmento, composições, formulação, cristal de anticorpo ou seu fragmento, método de tratamento e métodos de produção de cristais e de gel de proteìna de anticorpo ou seu fragmento
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US7935790B2 (en) 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006053301A2 (en) 2004-11-12 2006-05-18 Xencor, Inc. Fc variants with altered binding to fcrn
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
US7807789B2 (en) 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
US20060142234A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
KR20070107079A (ko) * 2005-01-28 2007-11-06 와이어쓰 안정화된 액체 폴리펩타이드 제형
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
EP1698637B1 (en) * 2005-03-03 2008-10-15 Ajinomoto Co., Inc. A method for improving recovery yield in protein purification with gel filtration chromatography using arginine
AU2012200203B2 (en) * 2005-03-08 2014-07-03 Pfizer Products Inc. Anti-CTLA-4 Antibody Compositions
PT2620450T (pt) * 2005-03-08 2018-12-17 Pfizer Prod Inc Composições de anticorpos anti-ctla-4
AU2014240252B2 (en) * 2005-03-08 2016-10-06 Pfizer Products Inc Anti-CTLA-4 Antibody Compositions
EP3195874A1 (en) 2005-03-25 2017-07-26 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations
CN101166763B (zh) 2005-04-18 2012-09-19 伊达研究和发展有限公司 稳定的抗乙肝病毒(hbv)抗体配制剂
JP5129122B2 (ja) 2005-04-26 2013-01-23 トリオン ファーマ ゲーエムベーハー 癌治療のための抗体およびグルココルチコイドの組み合わせ
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
US20060286171A1 (en) * 2005-06-17 2006-12-21 Tianhong Zhou Bone morphogenetic protein formulations
WO2007027906A2 (en) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
PL1942939T5 (pl) * 2005-09-30 2021-10-11 Medimmune Limited Kompozycja przeciwciała interleukiny-13
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
EP1962886B2 (en) * 2005-12-20 2022-02-23 Bristol-Myers Squibb Company Stable protein formulations
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
CN106589132B (zh) 2005-12-20 2022-03-29 布里斯托尔-迈尔斯斯奎布公司 组合物和用于生产组合物的方法
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
AU2006330858A1 (en) 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
CA3022097C (en) 2006-03-15 2020-10-27 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
AU2007229554A1 (en) * 2006-03-28 2007-10-04 F. Hoffmann-La Roche Ag Anti-IGF-1R human monoclonal antibody formulation
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
BRPI0710826A2 (pt) * 2006-04-21 2011-08-23 Novartis Ag composições farmacêuticas de anticorpo anti-cd40 antagonista
KR101406811B1 (ko) * 2006-06-16 2014-06-12 리제너론 파마슈티칼스 인코포레이티드 유리체내 투여에 적당한 ｖｅｇｆ 길항제 제형
US7964574B2 (en) 2006-08-04 2011-06-21 Baxter International Inc. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
US7939636B2 (en) 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
RS53263B (en) 2006-08-14 2014-08-29 Xencor Inc. CD19 OPTIMIZED ANTIBODY
PT2061810E (pt) 2006-09-05 2015-02-05 Alexion Pharma Inc Métodos e composições para o tratamento de neuropatias mediadas por anticorpos
US7744890B2 (en) * 2006-10-12 2010-06-29 Wyeth Llc Methods and compositions with reduced opalescence
EP2094729A1 (en) * 2006-12-11 2009-09-02 F.Hoffmann-La Roche Ag Abeta antibody parenteral formulation
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
US20090081659A1 (en) 2007-03-07 2009-03-26 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US20090068684A1 (en) 2007-03-26 2009-03-12 Cell Signaling Technology, Inc. Serine and threoninephosphorylation sites
MX2009010361A (es) 2007-03-29 2009-10-16 Abbott Lab Anticuerpos il-12 anti-humanos cristalinos.
JP5456658B2 (ja) * 2007-03-30 2014-04-02 メディミューン，エルエルシー 抗体製剤
US8808747B2 (en) * 2007-04-17 2014-08-19 Baxter International Inc. Nucleic acid microparticles for pulmonary delivery
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP2145902A3 (en) 2007-04-19 2010-09-29 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
EP1983003A3 (en) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
AU2008255016B2 (en) * 2007-05-15 2013-05-09 Stryker Corporation Concentrated protein preparations of bone morphogenetic proteins and methods of use thereof
DK2176298T3 (en) 2007-05-30 2018-02-12 Xencor Inc Methods and compositions for inhibiting CD32B-expressing cells
EP2170283B1 (en) 2007-06-22 2019-01-09 Board of Regents, The University of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
US20110014676A1 (en) * 2007-06-29 2011-01-20 Battelle Memorial Institute Protein stabilization
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
US20100189721A1 (en) * 2007-07-06 2010-07-29 Smithkline Beecham Corporation Antibody formulations
EP2167127A1 (en) * 2007-07-10 2010-03-31 F. Hoffmann-Roche AG Novel formulation
EP2182983B1 (en) 2007-07-27 2014-05-21 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
CA2695697A1 (en) 2007-08-07 2009-02-12 Advanced Technologies And Regenerative Medicine, Llc Protein formulations comprising gdf-5 in aqueous acidic solution
WO2009037190A2 (en) * 2007-09-21 2009-03-26 F. Hoffmann-La Roche Ag Pharmaceutical formulation for il-ir antibody
EP2205280B1 (en) 2007-09-27 2019-09-04 Amgen Inc. Pharmaceutical formulations
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US20090203043A1 (en) 2007-11-21 2009-08-13 Peter Hornbeck Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways
US20110177963A1 (en) * 2007-11-28 2011-07-21 Yale Unversity Variation in the CHI3L1 Gene Influences Serum YKL-40 Levels, Asthma Risk and Lung Function
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
WO2009073569A2 (en) * 2007-11-30 2009-06-11 Abbott Laboratories Protein formulations and methods of making same
SI2808343T1 (sl) 2007-12-26 2019-10-30 Xencor Inc Fc-variante s spremenjeno vezavo na FcRn
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
BRPI0822447A2 (pt) 2008-03-14 2015-06-16 Biocon Ltd Anticorpo monoclonal e método do mesmo
US7947649B2 (en) * 2008-04-14 2011-05-24 Advanced Technologies And Regenerative Medicine, Llc Liquid buffered GDF-5 formulations
WO2010042705A1 (en) * 2008-10-09 2010-04-15 Medimmune, Llc Antibody formulation
CN104740631B (zh) * 2008-10-29 2019-04-16 阿布林克斯公司 单域抗原结合性分子的制剂
US10118962B2 (en) 2008-10-29 2018-11-06 Ablynx N.V. Methods for purification of single domain antigen binding molecules
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2010056657A2 (en) * 2008-11-16 2010-05-20 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
MX2011005051A (es) * 2008-11-17 2011-06-01 Genentech Inc Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas.
RU2011126338A (ru) * 2008-11-28 2013-01-10 Эбботт Лэборетриз Стабильные композиции антител и способы их стабилизации
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
EP2391384A4 (en) * 2009-01-29 2012-12-26 Medimmune Llc HUMAN ANTI-IL-6 ANTIBODIES WITH EXTENDED IN VIVO HALF-TIME AND USE THEREOF FOR TREATMENTS IN ONCOLOGY AND FOR AUTOIMMUNE AND IGNITION
WO2010100135A1 (en) 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
SG174258A1 (en) 2009-03-06 2011-10-28 Genentech Inc Antibody formulation
US9056896B2 (en) 2009-03-27 2015-06-16 Asahi Kasei Medical Co., Ltd. Method for removing viruses from high concentration monoclonal antibody solution
JP2012526121A (ja) * 2009-05-04 2012-10-25 アボツト・バイオテクノロジー・リミテツド ヒト抗ｔｎｆアルファ抗体の安定した高蛋白質濃度製剤
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
US8454956B2 (en) * 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2473527B1 (en) 2009-09-03 2016-11-30 Ablynx N.V. Stable formulations of polypeptides and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
KR101832510B1 (ko) * 2009-10-26 2018-02-26 제넨테크, 인크. 치료 항-ｉｇｅ 항체에 대해 특이적인 항체를 검출하기 위한 검정 및 아나필락시스에서의 이의 용도
KR102071834B1 (ko) 2009-10-26 2020-01-30 에프. 호프만-라 로슈 아게 글리코실화된 면역글로불린의 제조 방법
EP3721904B1 (en) * 2009-11-20 2021-10-13 Biocon Limited Formulations of t1h antibody
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
TWI609698B (zh) 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd 穩定化的含抗體溶液製劑
WO2011104557A1 (en) 2010-02-24 2011-09-01 Arecor Limited Protein formulations
JP2013520476A (ja) 2010-02-26 2013-06-06 ノヴォ ノルディスク アー／エス 安定な抗体含有組成物
EP2542221A4 (en) * 2010-03-01 2013-10-23 Cytodyn Inc CONCENTRATED PROTEIN FORMULATIONS AND USES THEREOF
SI2542257T1 (en) 2010-03-01 2018-01-31 Bayer Healthcare Llc Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI)
US20130171128A1 (en) * 2010-03-02 2013-07-04 Amgen Inc. Reducing viscosity of pharmaceutical formulations
KR20180000342A (ko) 2010-03-22 2018-01-02 제넨테크, 인크. 단백질-함유 제제의 안정화에 유용한 조성물 및 방법
BR112012027828A2 (pt) * 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
US20130136733A1 (en) * 2010-05-28 2013-05-30 Novo Nordisk A/S Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
JO3659B1 (ar) * 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
EP2399604A1 (en) * 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
EA032336B1 (ru) 2010-09-17 2019-05-31 Баксалта Инкорпорейтид Стабильная водная иммуноглобулиновая композиция и способ стабилизации иммуноглобулиновой композиции
EP3354280B1 (en) 2010-10-06 2020-07-29 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
KR20190120439A (ko) 2010-11-08 2019-10-23 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체
EP2637690B1 (en) 2010-11-11 2016-09-21 AbbVie Biotechnology Ltd HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY LIQUID FORMULATIONS
KR20140043313A (ko) 2011-01-13 2014-04-09 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
SI2668212T1 (en) 2011-01-28 2018-08-31 Sanofi Biotechnology, Human antibodies against PCSK9 for use in the treatment processes of certain groups of subjects
EP3058952A1 (en) * 2011-04-07 2016-08-24 Glaxosmithkline LLC Formulations with reduced viscosity
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
ME02858B (me) 2011-05-02 2018-04-20 Millennium Pharm Inc Formulacija za anti- 4 7 antitelo
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2773111T3 (es) 2011-09-16 2020-07-09 Regeneron Pharma Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
PL2766397T3 (pl) 2011-10-11 2018-10-31 F.Hoffmann-La Roche Ag Ulepszone składanie przeciwciał bispecyficznych
KR102196009B1 (ko) * 2011-10-25 2021-01-04 프로테나 바이오사이언시즈 리미티드 항체 제형 및 방법
ES2937409T3 (es) 2011-10-28 2023-03-28 Prothena Biosciences Ltd Anticuerpos humanizados que reconocen la alfa-sinucleína
CN104023748B (zh) * 2011-10-28 2018-03-02 诚信生物公司 含有氨基酸的蛋白质制剂
KR20140084078A (ko) 2011-10-31 2014-07-04 제넨테크, 인크. 항체 제제
JP6113756B2 (ja) 2012-01-23 2017-04-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ａｎｇ２抗体を含有する安定化製剤
EP2807188B1 (en) 2012-01-27 2019-09-11 Prothena Biosciences Limited Humanized antibodies that recognize alpha-synuclein
AU2013262083A1 (en) * 2012-05-14 2014-11-06 Novo Nordisk A/S Stabilised protein solutions
EP2849723B1 (en) * 2012-05-18 2018-05-02 Genentech, Inc. High-concentration monoclonal antibody formulations
AR092325A1 (es) 2012-05-31 2015-04-15 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
JP6157611B2 (ja) * 2012-06-21 2017-07-05 ユセベ ファルマ ソシエテ アノニム 医薬製剤
WO2014015133A1 (en) 2012-07-19 2014-01-23 National Cheng Kung University Treatment of osteoarthritis using il-20 antagonists
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
FR2995213A1 (fr) * 2012-09-12 2014-03-14 Lfb Biotechnologies Seringue contenant une composition, notamment pharmaceutique, comprenant des immunoglobulines, son procede de fabrication et son utilisation
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
JP2015536934A (ja) * 2012-10-25 2015-12-24 メディミューン，エルエルシー 安定した低粘度の抗体製剤
EP2727602A1 (en) 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
WO2015000865A1 (en) 2013-07-04 2015-01-08 F. Hoffmann-La Roche Ag Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
WO2015011658A1 (en) 2013-07-23 2015-01-29 Biocon Limited Use of a cd6 binding partner and method based thereon
EP3808338A1 (en) 2013-09-11 2021-04-21 Eagle Biologics, Inc. Liquid protein formulations containing ionic liquids
US20160250329A1 (en) * 2013-10-29 2016-09-01 Albumedix A/S Antibody composition
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
ES2572919T3 (es) 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
EP2946767B1 (en) 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
PT2946765T (pt) 2014-05-23 2016-11-10 Ares Trading Sa Composição farmacêutica líquida
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
KR20230074283A (ko) 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
JP6685276B2 (ja) 2014-07-18 2020-04-22 サノフイＳａｎｏｆｉ 癌に罹患していることが疑われる患者のアフリベルセプトを用いた処置の結果を予測するための方法
WO2016019969A1 (en) 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
WO2016054259A1 (en) 2014-10-01 2016-04-07 Arsia Therapeutics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
RU2017111228A (ru) * 2014-10-18 2018-11-21 Пфайзер Инк. Композиции антитела против IL-7R
MA54716A (fr) * 2014-10-23 2021-11-17 Amgen Inc Réduction de la viscosité de formulations pharmaceutiques
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
WO2016115475A1 (en) * 2015-01-18 2016-07-21 Biogen Ma Inc. Anti-cd40 antibody formulations
US10550173B2 (en) 2015-02-19 2020-02-04 Compugen, Ltd. PVRIG polypeptides and methods of treatment
CN107580500B (zh) 2015-02-19 2023-05-30 康姆普根有限公司 抗pvrig抗体和使用方法
AR103726A1 (es) 2015-02-27 2017-05-31 Merck Sharp & Dohme Cristales de anticuerpos monoclonales anti-pd-1 humanos
LT3313879T (lt) 2015-06-24 2022-03-25 F. Hoffmann-La Roche Ag Antikūnai prieš transferino receptorių su pritaikytu giminingumu
US20180305451A1 (en) 2015-07-13 2018-10-25 Compugen Ltd. Hide1 compositions and methods
EP4209499A1 (en) 2015-08-13 2023-07-12 Amgen Inc. Charged depth filtration of antigen-binding proteins
CN107922507B (zh) 2015-08-18 2022-04-05 瑞泽恩制药公司 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
NZ741067A (en) 2015-10-02 2023-07-28 Hoffmann La Roche Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
WO2017066714A1 (en) 2015-10-16 2017-04-20 Compugen Ltd. Anti-vsig1 antibodies and drug conjugates
KR102261636B1 (ko) 2015-12-03 2021-06-07 리제너론 파마슈티칼스 인코포레이티드 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법
KR20180088906A (ko) 2015-12-18 2018-08-07 아스텔라스세이야쿠 가부시키가이샤 항인간 tslp 수용체 항체 함유 의약 조성물
CN115400220A (zh) 2015-12-30 2022-11-29 豪夫迈·罗氏有限公司 减少聚山梨酯降解的制剂
CN109475623B (zh) * 2016-04-28 2023-05-26 比奥根Ma公司 用于临床使用抗血树突细胞抗原2抗体的药物组合物和给药方案
ES2963807T3 (es) 2016-06-08 2024-04-02 Xencor Inc Tratamiento de enfermedades relacionadas con la IgG4 con anticuerpos anti-CD19 de reticulación a CD32B
ES2770674T3 (es) * 2016-06-10 2020-07-02 Octapharma Ag Composición de inmunoglobulinas de alta concentración para aplicaciones farmacéuticas
JP7170329B2 (ja) 2016-09-16 2022-11-14 ロイコケア・アクチェンゲゼルシャフト 処理中の生物医薬製品の安定化のための新規な方法
JP7275027B2 (ja) 2016-10-06 2023-05-17 アムジェン インコーポレイテッド 粘度低下タンパク質医薬製剤
AU2017345454A1 (en) 2016-10-19 2019-05-30 Invenra Inc. Antibody constructs
EA201990998A1 (ru) 2016-10-21 2019-11-29 Фармацевтические составы и способы их получения
EP3529274B1 (en) 2016-10-21 2024-04-17 Biocon Limited A monoclonal antibody and a method of use for the treatment of lupus
AU2017383142A1 (en) 2016-12-22 2019-07-04 Università Degli Studi Magna Graecia Catanzaro A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of CD43
US11203636B2 (en) 2017-02-01 2021-12-21 Yale University Treatment of existing left ventricular heart failure
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
JP7179717B2 (ja) 2017-03-31 2022-11-29 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 水性製剤及び注射器入り水性製剤、並びに、抗体タンパク脱凝集剤及び抗体タンパク脱凝集方法
US10799597B2 (en) 2017-04-03 2020-10-13 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
CA3060581A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3630180A1 (en) 2017-06-01 2020-04-08 Compugen Ltd. Triple combination antibody therapies
SG11202000298VA (en) 2017-07-14 2020-02-27 Pfizer Antibodies to madcam
EP3658184B1 (en) 2017-07-27 2023-09-06 Alexion Pharmaceuticals, Inc. High concentration anti-c5 antibody formulations
CA3073066A1 (en) 2017-08-22 2019-02-28 Biogen Ma Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
MA49948A (fr) * 2017-08-22 2020-07-01 Biogen Ma Inc Compositions pharmaceutiques et schémas posologiques contenant des anticorps anti-alpha (v) bêta (6)
CA3074565A1 (en) 2017-09-05 2019-03-14 Merck Sharp & Dohme Corp. Compounds for reducing the viscosity of biological formulations
IL297354A (en) * 2017-11-30 2022-12-01 Bio Thera Solutions Ltd A liquid preparation of a humanized antibody for the treatment of 6-il-related disease
CA3087699A1 (en) 2018-01-05 2019-07-11 Corvidia Therapeutics, Inc. Methods for treating il-6 mediated inflammation without immunosuppression
WO2019153200A1 (zh) 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
CA3226165A1 (en) 2018-02-09 2019-08-15 Genentech, Inc. Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
US20210115155A1 (en) * 2018-03-26 2021-04-22 Novartis Ag Methods of treating chronic spontaneous urticaria using ligelizumab
US11103552B2 (en) 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CA3102349A1 (en) 2018-06-05 2019-12-12 King's College London Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
TW202011995A (zh) * 2018-07-03 2020-04-01 比利時商葛萊伯格有限公司 高濃度液體抗體配製物
WO2020051307A1 (en) * 2018-09-05 2020-03-12 Ventria Bioscience Inc. Formulations of immunoglobulin a
BR112021004590A2 (pt) 2018-09-12 2021-05-25 Silverback Therapeutics, Inc. composições para o tratamento de doença com conjugados imunoestimuladores
WO2020087003A1 (en) * 2018-10-26 2020-04-30 Amgen Inc. Formulations comprising a tris buffer and a protein
JP2022519828A (ja) 2019-01-31 2022-03-25 サノフィ・バイオテクノロジー 若年性特発性関節炎を治療するための抗ｉｌ－６受容体抗体
UA128098C2 (uk) 2019-02-18 2024-04-03 Елі Ліллі Енд Компані Водна фармацевтична композиція антитіла проти il-17a
US11730812B2 (en) * 2019-03-08 2023-08-22 Boehringer Ingelheim International Gmbh Anti-IL-36R antibody formulations
CN114341185A (zh) 2019-06-19 2022-04-12 希沃尔拜克治疗公司 抗间皮素抗体及其免疫缀合物
US20220280643A1 (en) * 2019-07-29 2022-09-08 Mark White Anti-pvrig antibodies formulations and uses thereof
CA3152838A1 (en) * 2019-08-30 2021-03-04 Kashiv Biosciences, Llc Novel formulation of highly concentrated pharmacologically active antibody
CN112516090B (zh) * 2019-09-18 2023-06-20 上海复旦张江生物医药股份有限公司 抗体偶联药物的药物组合、冷冻干燥剂及制备方法、用途
EP3808777A1 (en) 2019-10-16 2021-04-21 Glenmark Specialty S.A. Stable liquid antibody formulations
JP2023500651A (ja) * 2019-11-04 2023-01-10 コンピュジェン リミテッド 抗ｐｖｒｉｇ抗体製剤および抗ｐｄ－１抗体による併用療法
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
US20230131324A1 (en) * 2020-02-24 2023-04-27 Medimmune, Llc Formulations of anti-endothelial lipase antibodies
CA3183993A1 (en) 2020-07-01 2022-01-06 Peter R. Baum Anti-asgr1 antibody conjugates and uses thereof
CN114762727A (zh) * 2021-01-15 2022-07-19 海正生物制药有限公司 一种稳定的帕妥珠单抗的药物组合物
EP4308148A1 (en) * 2021-03-16 2024-01-24 Kashiv Biosciences, LLC Novel formulation of fusion protein
WO2022245859A1 (en) 2021-05-17 2022-11-24 Curia Ip Holdings, Llc Sars-cov-2 spike protein antibodies
WO2022245877A1 (en) 2021-05-17 2022-11-24 Curia Ip Holdings, Llc Sars-cov-2 spike protein antibodies
EP4355362A1 (en) 2021-06-14 2024-04-24 Novartis AG Pharmaceutical formulation containing an anti-ige antibody
EP4355111A2 (en) * 2021-06-18 2024-04-24 Techmix, LLC Bovine supplement for neonatal calves
TW202325731A (zh) * 2021-08-16 2023-07-01 美商麥迪紐有限責任公司 抗ｉｌ—１３抗體調配物
CN114159555A (zh) * 2021-12-08 2022-03-11 江西赛基生物技术有限公司 抗原蛋白冻干小球及其制备方法

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
CA1064396A (en) * 1975-02-18 1979-10-16 Myer L. Coval Fractional precipitation of gamma globulin with polyethylene glycol
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4374763A (en) † 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4375763A (en) 1980-10-14 1983-03-08 Agl Corporation Device for detecting and locating leaks in pipelines
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4499073A (en) * 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
AU610083B2 (en) 1986-08-18 1991-05-16 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4946783A (en) 1987-01-30 1990-08-07 President And Fellows Of Harvard College Periplasmic protease mutants of Escherichia coli
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4940782A (en) * 1987-06-08 1990-07-10 G. D. Searle & Co. Monoclonal antibodies against IgE-associated determinants, hybrid cell lines producing these antibodies, and use therefore
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
ES2044941T5 (es) 1987-08-21 1999-02-16 Mallinckrodt Group Inc Estabilizador de hormonas promotoras del crecimiento.
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
JP2755395B2 (ja) 1987-09-23 1998-05-20 ブリストル―マイアーズ スクイブ コムパニー Ｈｉｖ感染細胞に殺作用する抗体異種結合体
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
ATE105585T1 (de) 1987-12-21 1994-05-15 Univ Toledo Transformation von keimenden pflanzensamen mit hilfe von agrobacterium.
CA1331133C (en) * 1988-03-01 1994-08-02 Michael Jon Pikal Pharmaceutical growth hormone formulations
ATE117434T1 (de) * 1988-03-30 1995-02-15 Toray Industries Gefriergetrocknete zusammensetzung, die ein mit meerrettichperoxydase markiertes fab'-fragment eines gegen menschliches beta-interferon gerichteten antikörpers und trehalose enthält; eia kit, der diese zusammensetzung enthält.
US5215743A (en) * 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
GB2218703B (en) * 1988-05-10 1992-10-28 Sumitomo Chemical Co Human monoclonal antibody to p.aeruginosa: its production and use
WO1989011297A1 (en) 1988-05-27 1989-11-30 Centocor, Inc. Freeze-dried formulation for antibody products
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
WO1990011091A1 (en) 1989-03-27 1990-10-04 Centocor, Inc. FORMULATIONS FOR STABILIZING OF IgM ANTIBODIES
ZA902663B (en) 1989-04-07 1991-12-24 Syntex Inc Interleukin-1 formulation
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0394538B1 (en) 1989-04-28 1996-10-16 Rhein Biotech Gesellschaft Für Neue Biotechnologische Prozesse Und Produkte Mbh A yeast cell of the genus schwanniomyces
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DK0479909T3 (da) 1989-06-29 1997-04-07 Medarex Inc Bispecifikke reagenser til AIDS-behandling
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
WO1992017207A1 (en) 1991-03-26 1992-10-15 Tanox Biosystems, Inc. MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
JP2966592B2 (ja) 1991-07-20 1999-10-25 萩原 義秀 安定化されたヒトモノクローナル抗体製剤
US6329509B1 (en) 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
US6685939B2 (en) * 1991-08-14 2004-02-03 Genentech, Inc. Method of preventing the onset of allergic disorders
ES2296839T3 (es) 1991-08-14 2008-05-01 Genentech Inc. Variantes de inmunoglobulinas para receptores fc-epsilon especificos.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
GB9120304D0 (en) 1991-09-24 1991-11-06 Erba Carlo Spa Stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2122732C (en) 1991-11-25 2008-04-08 Marc D. Whitlow Multivalent antigen-binding proteins
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
ATE503496T1 (de) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic Biosynthetisches bindeprotein für tumormarker
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
AU670793B2 (en) * 1992-04-30 1996-08-01 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor VIII complex
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
ES2151541T3 (es) 1992-12-02 2001-01-01 Alkermes Inc Microesferas que contienen hormona del crecimiento de liberacion prolongada.
DE4344824C1 (de) 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
GB9418092D0 (en) * 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
CA2196184C (en) 1994-09-09 2009-06-09 Yasutaka Igari Sustained release preparation containing metal salt of a peptide
WO1996016673A1 (en) 1994-12-02 1996-06-06 Chiron Corporation Method of promoting an immune response with a bispecific antibody
DE69521605T2 (de) 1994-12-28 2002-05-08 Rhone Poulenc Chimie Optisch aktive diphosphine und herstellungsverfahren durch auftrennung der racematmischung
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6037453A (en) * 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
PT831787E (pt) 1995-06-07 2002-02-28 Alkermes Inc Composicao para libertacao sustentada da hormona de crescimento humano
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
AU716785B2 (en) 1995-07-27 2000-03-09 Genentech Inc. Stabile isotonic lyophilized protein formulation
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
KR100236393B1 (ko) 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US6096872A (en) * 1997-10-14 2000-08-01 Ortho Diagnostic Systems, Inc. Viral clearance process
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
WO2000015260A1 (en) 1998-09-16 2000-03-23 Tanox, Inc. Anti-ige gene therapy
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
HU0800692D0 (en) 1999-10-04 2009-01-28 Novartis Vaccines & Diagnostic Stabilized liquid polypeptide-containing pharmaceutical compositions
WO2001040264A2 (en) * 1999-12-06 2001-06-07 Panacea Pharmaceuticals, Llc. Peptide antigens
AU2001244584B2 (en) 2000-03-31 2006-01-19 Kirin Pharma Kabushiki Kaisha Powdery preparation for transmucosal administration containing a polymeric form of drug and exhibiting improved storage stability
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
GB0023383D0 (en) * 2000-09-23 2000-11-08 Synprotec Ltd 3,5-Bis (Trifluormethyl)Benzene derivatives
CN1469756A (zh) 2000-10-11 2004-01-21 江头健辅 治疗肝病的药物
DE60139944D1 (de) 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
JP4731793B2 (ja) 2000-12-28 2011-07-27 アルセア テクノロジーズ インコーポレイテッド 抗体全体またはそのフラグメントの結晶、ならびにこの結晶を作製および使用するための方法
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
JP4317010B2 (ja) * 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
BR0213298A (pt) * 2001-10-16 2006-11-07 Rxkinetix Inc formulações com alta concentração de proteìna e processo de fabricação
DK1441589T3 (da) † 2001-11-08 2012-08-06 Abbott Biotherapeutics Corp Stabil, flydende, farmaceutisk sammensætning af IgG-antistoffer
AU2003267905B2 (en) 2002-10-04 2009-02-05 Biolnvent International Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
US20040191243A1 (en) * 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
PT1610820E (pt) † 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
CA2674608A1 (en) 2007-01-09 2008-07-17 Wyeth Anti-il-13 antibody formulations and uses thereof
BRPI0821600A2 (pt) 2007-12-28 2015-06-23 Bioinvent Int Ab Composição farmacêutica, artigo de fabricação, kit de partes, método de combater aterosclerose, ou uma doença cardiovascular associada à aterosclerose, e, uso de um anticorpo
SG174258A1 (en) 2009-03-06 2011-10-28 Genentech Inc Antibody formulation

Also Published As

Publication number Publication date
CL2004000731A1 (es) 2005-05-20
NO342573B1 (no) 2018-06-18
TNSN05229A1 (en) 2007-06-11
AU2004229335B2 (en) 2009-12-03
ZA200507757B (en) 2007-01-31
NO338143B1 (no) 2016-08-01
ECSP14011269A (es) 2015-12-31
KR101195295B1 (ko) 2012-10-29
MA27773A1 (fr) 2006-02-01
CY1118467T1 (el) 2017-07-12
PT1610820E (pt) 2010-12-16
CY1111232T1 (el) 2015-06-11
EP3178492A1 (en) 2017-06-14
US20120064086A1 (en) 2012-03-15
NZ542964A (en) 2008-06-30
DK1610820T4 (da) 2013-11-04
HUE030579T2 (en) 2017-05-29
PL1610820T3 (pl) 2011-03-31
AR104198A2 (es) 2017-07-05
EP1610820B1 (en) 2010-09-08
SI2335725T1 (sl) 2017-01-31
NO20180694A1 (no) 2005-11-04
US20070053900A1 (en) 2007-03-08
DK1610820T3 (da) 2010-11-29
US10034940B2 (en) 2018-07-31
US20040197324A1 (en) 2004-10-07
US20090280129A1 (en) 2009-11-12
US20190358323A1 (en) 2019-11-28
PL1610820T5 (pl) 2014-01-31
KR20110067067A (ko) 2011-06-20
JP5449268B2 (ja) 2014-03-19
TW200505480A (en) 2005-02-16
ES2349779T5 (es) 2013-11-26
AU2010200784B2 (en) 2011-11-17
AU2004229335C1 (en) 2010-06-17
EP1610820A1 (en) 2006-01-04
CN102258464A (zh) 2011-11-30
BRPI0403964B8 (pt) 2021-05-25
CL2017000208A1 (es) 2017-06-23
BRPI0403964B1 (pt) 2020-10-06
JP2011246484A (ja) 2011-12-08
MY172641A (en) 2019-12-07
CA2519408C (en) 2011-01-18
CL2013000142A1 (es) 2013-04-01
WO2004091658A1 (en) 2004-10-28
ES2609010T3 (es) 2017-04-18
CO5660273A2 (es) 2006-07-31
PL2335725T3 (pl) 2017-04-28
HRP20050934B1 (hr) 2014-09-26
EP2335725B1 (en) 2016-10-12
AU2004229335A1 (en) 2004-10-28
HRP20050934A2 (en) 2006-06-30
US8961964B2 (en) 2015-02-24
KR20060017583A (ko) 2006-02-24
BRPI0403964A (pt) 2005-03-01
EP1610820B2 (en) 2013-08-21
LT2335725T (lt) 2017-01-25
TWI357820B (en) 2012-02-11
DK2335725T3 (en) 2017-01-23
CN1798575A (zh) 2006-07-05
CA2519408A1 (en) 2004-10-28
IL228034A0 (en) 2013-09-30
US20170049888A1 (en) 2017-02-23
ATE480567T1 (de) 2010-09-15
RU2005134236A (ru) 2006-06-10
EP2335725A1 (en) 2011-06-22
NO20160963A1 (no) 2016-06-03
AU2010200784A1 (en) 2010-03-25
PT2335725T (pt) 2017-01-06
IL170866A (en) 2013-09-30
KR101208291B1 (ko) 2012-12-05
US20150225485A1 (en) 2015-08-13
HK1085933A1 (en) 2006-09-08
JP4869064B2 (ja) 2012-02-01
DE602004029015D1 (de) 2010-10-21
RU2332986C2 (ru) 2008-09-10
NO20055202L (no) 2005-11-04
AR043826A1 (es) 2005-08-17
PE20050394A1 (es) 2005-06-19
ECSP056142A (es) 2006-04-19
JP2007524602A (ja) 2007-08-30
ES2349779T3 (es) 2011-01-11

Similar Documents

Publication Publication Date Title
TNSN05229A1 (en) High concentration antibody and protein formulations
WO2006065746A3 (en) Methods of treating ige-mediated disorders comprising the administration of high concentration anti-ige antibody formulations
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
EA200801570A1 (ru) Стабильные белковые препараты
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
AU2002364082A1 (en) Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
EA200500169A1 (ru) Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение
AU2002359727A1 (en) Fused cyclic modulators of nuclear hormone receptor function
MXPA06011327A (es) Azaindoles utiles como inhibidores de jak y otras proteinas cinasas.
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
UA86599C2 (en) Substituted benzimidazole-, benztriazole- and benzimidazolone-о-glucosides
WO2005016962A3 (en) Compositions and methods for the treatment of immune related diseases
GB0305929D0 (en) Organic compounds
EP1670450B8 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
WO2007076085A3 (en) Fused pyrimidones and thiopyrimidones, and uses thereof
JO2795B1 (en) Immunoglobulins
UA87494C2 (en) Azaindoles useful as inhibitors of jak and other protein kinases
ATE389651T1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
ITMI20052515A1 (it) Formulazione farmaceutica per il trattamento della osteoartrite
MX2015005579A (es) Metodo para aislar synagis(r) en ausencia de benzonasa.
EA200600318A1 (ru) ПРОИЗВОДНЫЕ 3-НИТРОПИРАЗОЛО[1,5-a]ПИРИМИДИНОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ, ЛЕКАРСТВЕННОЕ СРЕДСТВО (ВАРИАНТЫ) И СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С МОДУЛЯЦИЕЙ РЕЦЕПТОРА ГАМК(ВАРИАНТЫ)
WO2001010382A3 (en) Compositions and methods related to claudin-7
RS20060322A (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides

Legal Events

Date Code Title Description
FG Grant or registration